MX2022000251A - Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. - Google Patents
Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo.Info
- Publication number
- MX2022000251A MX2022000251A MX2022000251A MX2022000251A MX2022000251A MX 2022000251 A MX2022000251 A MX 2022000251A MX 2022000251 A MX2022000251 A MX 2022000251A MX 2022000251 A MX2022000251 A MX 2022000251A MX 2022000251 A MX2022000251 A MX 2022000251A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- activation protein
- protein ligand
- fibroblast activation
- xaa1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19000325.1A EP3763726A1 (en) | 2019-07-08 | 2019-07-08 | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP19198810 | 2019-09-20 | ||
| PCT/EP2020/069308 WO2021005131A1 (en) | 2019-07-08 | 2020-07-08 | Compounds comprising a fibroblast activation protein ligand and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000251A true MX2022000251A (es) | 2022-02-21 |
Family
ID=71409440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000251A MX2022000251A (es) | 2019-07-08 | 2020-07-08 | Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220315554A1 (enExample) |
| EP (1) | EP3997104A1 (enExample) |
| JP (2) | JP7801207B2 (enExample) |
| KR (1) | KR20220032078A (enExample) |
| CN (3) | CN118955620A (enExample) |
| AU (2) | AU2020309161A1 (enExample) |
| BR (1) | BR112022000144A2 (enExample) |
| CA (1) | CA3145872A1 (enExample) |
| CL (1) | CL2022000016A1 (enExample) |
| IL (2) | IL324399A (enExample) |
| MX (1) | MX2022000251A (enExample) |
| WO (1) | WO2021005131A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3997103T3 (pl) | 2019-07-08 | 2025-03-24 | 3B Pharmaceuticals Gmbh | Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie |
| EP4147053B1 (en) | 2020-05-07 | 2026-01-28 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| CN116888138A (zh) * | 2020-11-30 | 2023-10-13 | 瑞择生物公司 | 放射性药物缀合组合物及其用途 |
| EP4050018A1 (en) * | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| EP4448544A2 (en) * | 2021-12-17 | 2024-10-23 | 3B Pharmaceuticals GmbH | Carbonic anhydrase ix ligands |
| EP4475900A1 (en) | 2022-02-09 | 2024-12-18 | Novartis AG | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
| IL322552A (en) | 2023-02-10 | 2025-10-01 | Chengdu New Radiomedicine Tech Co Ltd | Polypeptide compound and its use |
| JP2026510608A (ja) | 2023-02-14 | 2026-04-08 | ラーディオファックス ゲーエムベーハー | 薬物及び処置の方法 |
| CN118754936A (zh) * | 2023-03-27 | 2024-10-11 | 晶核生物医药科技(南京)有限公司 | 环状多肽类化合物及其应用 |
| EP4692105A1 (en) * | 2023-03-27 | 2026-02-11 | Bivision Pharmaceuticals, Inc | Cyclic polypeptide compound and use thereof |
| CN118754937A (zh) * | 2023-03-27 | 2024-10-11 | 晶核生物医药科技(南京)有限公司 | 环状多肽类化合物及其应用 |
| CN118930606A (zh) * | 2023-05-11 | 2024-11-12 | 成都纽瑞特医疗科技股份有限公司 | 靶向成纤维细胞活化蛋白的多肽放射性核素配合物及其应用 |
| TW202502800A (zh) * | 2023-07-11 | 2025-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種成纖維細胞活化蛋白配體及其用途 |
| AU2024334645A1 (en) * | 2023-08-31 | 2026-02-26 | Stichting Radboud Universitair Medisch Centrum | Endometriosis tracer |
| WO2025082283A1 (zh) * | 2023-10-16 | 2025-04-24 | 四川科伦博泰生物医药股份有限公司 | 环肽结构的配体化合物及其核素标记物、药物组合物及应用 |
| US20250186630A1 (en) | 2023-12-12 | 2025-06-12 | Viewpoint Molecular Targeting, Inc. | Fibroblast activation protein targeting peptides |
| AU2025214491A1 (en) | 2024-02-01 | 2026-08-06 | Novartis Ag | Methods for treating cancer |
| WO2026008525A1 (en) * | 2024-07-01 | 2026-01-08 | Bayer Aktiengesellschaft | Stable radionuclide-containing formulations |
| WO2026017046A1 (zh) * | 2024-07-19 | 2026-01-22 | 晶核生物医药科技(南京)有限公司 | 一种环多肽、其制备方法和应用 |
| WO2026021314A1 (zh) * | 2024-07-22 | 2026-01-29 | 山东威智知科药业有限公司 | Fap化合物及其用途 |
| WO2026041109A1 (zh) * | 2024-08-23 | 2026-02-26 | 苏州博锐创合医药有限公司 | 成纤维细胞活化蛋白抑制剂及其用途 |
| WO2026046340A1 (zh) * | 2024-08-30 | 2026-03-05 | 江苏恒瑞医药股份有限公司 | 一种f-18标记反应前体分子的方法 |
| WO2026056964A1 (zh) * | 2024-09-14 | 2026-03-19 | 四川科伦博泰生物医药股份有限公司 | 环肽结构的配体化合物及其核素标记物、药物组合物及应用 |
| WO2026149506A1 (zh) * | 2025-01-10 | 2026-07-16 | 天津恒瑞医药有限公司 | 一种药物组合物及其制备方法 |
| WO2026149529A1 (zh) * | 2025-01-10 | 2026-07-16 | 天津恒瑞医药有限公司 | 一种成纤维细胞活化蛋白配体及其用途 |
| WO2026163110A1 (en) | 2025-01-30 | 2026-08-06 | Novartis Ag | Combinations with fap targeting compounds and conjugates thereof |
| CN120590466B (zh) * | 2025-08-06 | 2026-05-12 | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 一种靶向成纤维细胞活化蛋白的化合物及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| JP2001518290A (ja) | 1997-09-29 | 2001-10-16 | ポイント セラピューティクス， インコーポレイテッド | インビトロでの造血細胞の刺激 |
| EP0953639A1 (en) | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| CA2401252A1 (en) | 2000-03-17 | 2001-09-20 | Boehringer Ingelheim Pharma Kg | Human and humanized fap-alpha-specific antibodies |
| EP1452868A2 (en) * | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| US7374898B2 (en) * | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
| CA2606785A1 (en) | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| CA2681351A1 (en) | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein, and methods of use thereof |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| CN102203061A (zh) | 2008-09-25 | 2011-09-28 | 分子制药洞察公司 | 选择性seprase抑制剂 |
| WO2011040972A1 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| PE20171512A1 (es) | 2010-08-13 | 2017-10-20 | Roche Glycart Ag | Anticuerpos anti-fap |
| WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| BR112014022435B1 (pt) * | 2012-03-21 | 2023-02-14 | Takeda Pharmaceutical Company Limited | Inibidores de tfpi e métodos de uso |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| CA2949936C (en) * | 2014-06-10 | 2022-10-18 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| WO2016146174A1 (en) | 2015-03-17 | 2016-09-22 | Biontech Ag | Compositions and methods for diagnosis and treatment of cancer |
| US11236123B2 (en) * | 2016-01-20 | 2022-02-01 | Polypeptide Laboratories Holding (Ppl) Ab | Method for preparation of peptides with psWang linker |
| CR20180581A (es) | 2016-06-10 | 2019-02-11 | Bayer Pharma AG | Complejos radio-farmacéuticos |
| CN105949282B (zh) * | 2016-06-20 | 2020-06-16 | 郑州大学 | 一种靶向fap的抗血管生成肽z-gp-v2及其应用 |
| CN106046121B (zh) * | 2016-06-20 | 2020-06-16 | 郑州大学 | 一种靶向fap的抗血管生成肽z-gp-v1及其应用 |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| JP2021500373A (ja) * | 2017-10-23 | 2021-01-07 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤 |
| PL3997103T3 (pl) * | 2019-07-08 | 2025-03-24 | 3B Pharmaceuticals Gmbh | Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie |
-
2020
- 2020-07-08 CN CN202411047668.1A patent/CN118955620A/zh active Pending
- 2020-07-08 CN CN202411047674.7A patent/CN118930608A/zh active Pending
- 2020-07-08 CN CN202080062641.3A patent/CN114341158B/zh active Active
- 2020-07-08 US US17/625,246 patent/US20220315554A1/en not_active Abandoned
- 2020-07-08 EP EP20735648.6A patent/EP3997104A1/en active Pending
- 2020-07-08 JP JP2022501191A patent/JP7801207B2/ja active Active
- 2020-07-08 CA CA3145872A patent/CA3145872A1/en active Pending
- 2020-07-08 IL IL324399A patent/IL324399A/en unknown
- 2020-07-08 IL IL289673A patent/IL289673B2/en unknown
- 2020-07-08 AU AU2020309161A patent/AU2020309161A1/en not_active Abandoned
- 2020-07-08 KR KR1020227004042A patent/KR20220032078A/ko not_active Ceased
- 2020-07-08 MX MX2022000251A patent/MX2022000251A/es unknown
- 2020-07-08 WO PCT/EP2020/069308 patent/WO2021005131A1/en not_active Ceased
- 2020-07-08 BR BR112022000144A patent/BR112022000144A2/pt unknown
-
2022
- 2022-01-04 CL CL2022000016A patent/CL2022000016A1/es unknown
-
2026
- 2026-01-05 JP JP2026000148A patent/JP2026062901A/ja active Pending
- 2026-04-08 AU AU2026202638A patent/AU2026202638A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021005131A1 (en) | 2021-01-14 |
| JP7801207B2 (ja) | 2026-01-16 |
| CN114341158A (zh) | 2022-04-12 |
| AU2020309161A1 (en) | 2022-01-27 |
| EP3997104A1 (en) | 2022-05-18 |
| IL289673B1 (en) | 2025-12-01 |
| AU2026202638A1 (en) | 2026-05-21 |
| IL324399A (en) | 2026-01-01 |
| CN118930608A (zh) | 2024-11-12 |
| CN118955620A (zh) | 2024-11-15 |
| IL289673B2 (en) | 2026-04-01 |
| IL289673A (en) | 2022-03-01 |
| JP2022541752A (ja) | 2022-09-27 |
| BR112022000144A2 (pt) | 2022-02-22 |
| CL2022000016A1 (es) | 2022-08-19 |
| KR20220032078A (ko) | 2022-03-15 |
| CA3145872A1 (en) | 2021-01-14 |
| JP2026062901A (ja) | 2026-04-10 |
| CN114341158B (zh) | 2024-08-06 |
| US20220315554A1 (en) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000016A1 (es) | Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo | |
| CL2024001597A1 (es) | Compuestos que comprenden un ligando de proteína de activación de fibroblasto y uso del mismo. | |
| MX2022000252A (es) | Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. | |
| PE20091753A1 (es) | Conjugados antagonistas peptidicos analogos a la bombesina | |
| MX2015011243A (es) | Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial. | |
| MX2016011934A (es) | Inmunoglobulina hibrida conteniendo un enlace no-peptidilico. | |
| PE20181889A1 (es) | Preparaciones que contienen anticuerpos | |
| JP2013177403A5 (enExample) | ||
| ES2585580T3 (es) | Péptidos novedosos antienvejecimiento y composición cosmética y/o farmacéutica que los contiene | |
| CO6150201A2 (es) | Anticuerpo humanizado contra beta amiloide | |
| AR058888A1 (es) | Formulaciones estabilizadas que contienen anticuerpos | |
| HRP20120621T1 (hr) | Sna“ni analozi kompstatina | |
| EA200601720A1 (ru) | Селективные агонисты рецептора y4 для терапевтического воздействия | |
| PH12016500403A1 (en) | An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof | |
| RU2015146739A (ru) | Комплексы типа сахаридная цепочка-полипептид | |
| CL2024001254A1 (es) | Ligandos de receptor de péptido inhibidor gástrico | |
| PH12021551055A1 (en) | Klk5 inhibitory peptide | |
| BR112015018283A2 (pt) | Composto peptídico agonista e composição farmacêutica ou veterinária | |
| ES2607490T3 (es) | Péptidos antienvejecimiento activadores del proteasoma y composiciones que los contienen | |
| RU2017122029A (ru) | Новые способы опосредованного ферментами конъюгирования полипептидов с использованием сортазы | |
| RU2013119051A (ru) | Тетрапептид и средство, обладающее церебропротекторной и антиамнестической активностями | |
| CO2024010813A2 (es) | Inhibidor de tsp1 | |
| CR20240470A (es) | Péptido con actividad antimicrobiana | |
| MX2024004272A (es) | Nueva proteina de polen de junipero. | |
| EP4541887A3 (en) | Compositions and methods for preparing factor xa and derivatives |